ARDELYX, INC. Current Federal Tax Expense (Benefit)
ARDELYX, INC. (ARDX) reported Current Federal Tax Expense (Benefit) of -$7.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2018-03-14
- ARDELYX, INC. current federal tax expense (benefit) for fiscal 2015 was -$7.00K.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2015-12-31 | -$7.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |